August 2012
-
The European Commission has approved Teva’s DuoResp Spiromax budesonide/formoterol DPI for the treatment of asthma and COPD, the company has announced. The EMA’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion… Read more . . .
-
NanoBio Corporation has announced that it will present promising pre-clinical study data of its nano-emulsion (NE)-adjuvanted intranasal herpes simplex virus-2 (HSV-2) vaccine at the Annual Conference on Vaccine Research. NanoBio Senior VP of Vaccine Research… Read more . . .
-
Civitas Therapeutics has announced positive results from a Phase 2b trial of its CVT-301 inhaled L-dopa for the treatment of Parkinson’s disease symptoms. The company is developing CVT-301 based on its proprietary ARCUS particle engineering… Read more . . .
-
GSK and Theravance have announced the launch of Anoro Ellipta umeclidinium/vilanterol inhalation powder in the United States, triggering a $30 million milestone payment from Theravance to GSK. The FDA approved Anoro Ellipta for the treatment… Read more . . .
-
Submit poster and paper abstracts by July 25, 2014 online at http://www.ddl-conference.org.uk/?q=abstractsubmissionDDL25. Visit http://www.ddl-conference.org.uk/index.php?q=abstractsubmission to view the session themes and download abstract guidelines. Read more . . .
-
The US FDA has proposed a new rule that would require e-cigarette makers to register with the agency, disclose ingredients used in their inhalation solutions, and provide scientific evidence to support claims of reduced risk… Read more . . .
-
Australia’s Therapeutic Goods Administration (TGA) has approved the Breo Ellipta fluticasone furoate/vilanterol for the treatment of asthma and COPD, according to GSK Australia and Theravance. GSK Medical Director Andrew Yeates commented, “We are delighted that… Read more . . .
-
The FDA has granted orphan drug designation to a ciprofloxacin DPI being developed by Bayer HealthCare for the treatment of non-cystic fibrosis bronchiectasis, the company has announced. The dry powder formulation, based on Novartis’s PulmoSphere… Read more . . .
-
Theravance has announced that its LABA Royalty Sub wholly owned subsidiary “issued $450 million in aggregate principal amount of PhaRMA 9% Notes due on or before May 15, 2029. The notes are secured by a… Read more . . .
-
GSK and Theravance have announced a Phase 3 study of fluticasone furoate (FF)/vilanterol (VI) (the Relvar Ellipta DPI) including Japanese COPD patients. In July 2013, GSK withdrew its application for Relvar for the treatment of… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland